Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 9/2003

01-09-2003 | Brief Report

Successful Treatment of an Aspergillus Brain Abscess with Caspofungin: Case Report of a Diabetic Patient Intolerant of Amphotericin B

Authors: A. L. Colombo, R. C. Rosas

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 9/2003

Login to get access

Excerpt

Aspergillosis may occur in a variety of clinical settings, including patients undergoing prolonged steroid therapy or cancer chemotherapy, patients who have undergone organ transplantation, or patients infected by the human immunodeficiency virus. Cerebral aspergillosis may occur in up to 20% of all cases of invasive aspergillosis; however, only in rare cases is the brain the sole site of infection [1]. Brain abscess due to Aspergillus spp. has been reported infrequently among immunologically competent patients [2]. We describe a diabetic patient with a brain abscess caused by Aspergillus spp. who was successfully treated with caspofungin, the first in a new class of antifungal agents known as the glucan synthesis inhibitors. …
Literature
1.
Denning DW (1998) Invasive aspergillosis. Clin Infect Dis 26:781–803PubMed
2.
Kim DG, Hong SC, Kim HJ, Chi JG, Han MH, Choi KS, Han DH (1993) Cerebral aspergillosis in immunologically competent patients. Surg Neurol 40:326–331PubMed
3.
Jinkins JR, Siqueira E, Al-Kawi MZ (1987) Cranial manifestations of aspergillosis. Neuroradiology 29:181–185PubMed
4.
Kawakami N, Nishizaki T, Sugiyama S, Ito H (1994) Aspergillus brain abscess in a patient with normal immunity—case report. Neurol Med Chir (Tokyo) 34:237–240
5.
Harari S (1999) Current strategies in the treatment of invasive Aspergillus infections in immunocompromised patients. Drugs 58:621–631PubMed
6.
Maertens J, Raad I, Petrikkos G, Selleslag D, Petersen F, Sable C, Kartsonis N, Ngai A, Taylor A, Patterson T, Denning D, Walsh T (2002) Update of the multicenter, noncomparative study of caspofungin in adults with invasive aspergillosis refractory or intolerant to other antifungal agents: an analysis of 90 patients. In: Program and abstracts, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. M-868
7.
Hedges TR, Leung LS (1976) Parasellar and orbital apex syndrome caused by aspergillosis. Neurology 26:117–120PubMed
8.
Galassi E, Pozzati E, Poppi M, Vinci A (1978) Cerebral aspergillosis following intracranial surgery. Case report. J Neurosurg 49:308–311PubMed
9.
Rodriguez-Hernandez MJ, Jimenez-Mejias ME, Montero JM, Regordan C, Ferreras G (2001) Aspergillus fumigatus cranial infection after accidental traumatism. Eur J Clin Microbiol Infect Dis 20:655–656CrossRefPubMed
Metadata
Title
Successful Treatment of an Aspergillus Brain Abscess with Caspofungin: Case Report of a Diabetic Patient Intolerant of Amphotericin B
Authors
A. L. Colombo
R. C. Rosas
Publication date
01-09-2003
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 9/2003
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-003-0991-6

Other articles of this Issue 9/2003

European Journal of Clinical Microbiology & Infectious Diseases 9/2003 Go to the issue

Article

Chronic Bronchitis in Immunocompromised Patients: Association with a Novel Mycoplasma Species

Announcements

September 2003

Concise Article

Plasmodium falciparum Cerebral Malaria Complicated by Disseminated Intravascular Coagulation and Symmetrical Peripheral Gangrene: Case Report and Review

Article

Diagnostic Accuracy of Otitis Media and Tympanocentesis Skills Assessment Among Pediatricians

Concise Article

Comparative In Vitro Activity of Faropenem and 11 Other Antimicrobial Agents Against 250 Invasive Streptococcus pneumoniae Isolates from France

Article

High Frequency of Antibiotic-Associated Diarrhea due to Toxin A-Negative, Toxin B-Positive Clostridium difficile in a Hospital in Japan and Risk Factors for Infection
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits